Published online before print August 3, 2006, doi: 10.1161/01.ATV.0000240050.15321.fe
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 American Heart Association, Inc.
Vascular Biology |
Angiotensin II Type 1 Receptor–Mediated Inflammation Is Required for Choroidal Neovascularization
From the Laboratory of Retinal Cell Biology (N.N., Y.O., K.I., Y.O., S.I.), Departments of Ophthalmology (N.N., K.I., K.N., Y.O., M.M.I., K.T., S.I.) and Cell Differentiation (N.N., Y.O., T.U., Y.K., T.S.), Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Correspondence to Susumu Ishida, MD, PhD, Laboratory of Retinal Cell Biology, Department of Ophthalmology, Keio University School of Medicine; 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. E-mail ishidasu{at}sc.itc.keio.ac.jp
Background— Choroidal neovascularization (CNV) is a critical pathogenesis in age-related macular degeneration, the most common cause of blindness in the developed countries. The aim of the current study was to determine the involvement of the renin-angiotensin system (RAS) with the development of CNV, using human surgical samples and the murine model of laser-induced CNV.
Methods and Results— In the human and murine CNV tissues, the vascular endothelium expressed angiotensin II type 1 receptor (AT1-R), AT2-R, and angiotensin II. The CNV volume was significantly suppressed by treatment with an AT1-R blocker telmisartan, but not with an AT2-R blocker. AT1-R signaling blockade with telmisartan inhibited various inflammatory mechanisms including macrophage infiltration and upregulation of VEGF, intercellular adhesion molecule-1 (ICAM-1), MCP-1, and IL-6 in the retinal pigment epithelium-choroid complex. A PPAR-
antagonist partially but significantly reversed the suppressive effect of telmisartan on in vivo induction of CNV and in vitro upregulation of ICAM-1 and MCP-1 in endothelial cells and IL-6 in macrophages, showing the dual contribution of PPAR--agonistic and AT1-R-antagonistic actions in the telmisartan treatment.
Conclusions— AT1-R–mediated inflammation plays a pivotal role in the development of CNV, indicating the possibility of AT1-R blockade as a novel therapeutic strategy to inhibit CNV.
We analyzed the involvement of the renin-angiotensin system with the development of choroidal neovascularizaron (CNV), using human surgical samples and the murine model of laser-induced CNV and revealed that angiotensin II type 1 receptor-mediated inflammation, including macrophage infiltration and cytokine upregulation, plays a pivotal role in the development of CNV.
Key Words: choroidal neovascularization • inflammation • intercellular adhesion molecule-1 • renin-angiotensin system • vascular endothelial growth factor
This article has been cited by other articles:
 |
|
 |
|
  H. Mochimaru, E. Takahashi, N. Tsukamoto, J. Miyazaki, T. Yaguchi, T. Koto, T. Kurihara, K. Noda, Y. Ozawa, T. Ishimoto, et al. Involvement of Hyaluronan and Its Receptor CD44 with Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., September 1, 2009; 50(9): 4410 - 4415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Okunuki, Y. Usui, N. Nagai, T. Kezuka, S. Ishida, M. Takeuchi, and H. Goto Suppression of Experimental Autoimmune Uveitis by Angiotensin II Type 1 Receptor Blocker Telmisartan Invest. Ophthalmol. Vis. Sci., May 1, 2009; 50(5): 2255 - 2261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sanchez-Lemus, J. Benicky, J. Pavel, I. M. Larrayoz, J. Zhou, M. Baliova, T. Nishioku, and J. M. Saavedra Angiotensin II AT1 blockade reduces the lipopolysaccharide-induced innate immune response in rat spleen Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2009; 296(5): R1376 - R1384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sasaki, Y. Ozawa, T. Kurihara, K. Noda, Y. Imamura, S. Kobayashi, S. Ishida, and K. Tsubota Neuroprotective Effect of an Antioxidant, Lutein, during Retinal Inflammation Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1433 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Izu, F. Mizoguchi, A. Kawamata, T. Hayata, T. Nakamoto, K. Nakashima, T. Inagami, Y. Ezura, and M. Noda Angiotensin II Type 2 Receptor Blockade Increases Bone Mass J. Biol. Chem., February 20, 2009; 284(8): 4857 - 4864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Wilkinson-Berka Prorenin and the (Pro)renin Receptor in Ocular Pathology Am. J. Pathol., December 1, 2008; 173(6): 1591 - 1594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Satofuka, A. Ichihara, N. Nagai, K. Noda, Y. Ozawa, A. Fukamizu, K. Tsubota, H. Itoh, Y. Oike, and S. Ishida (Pro)renin Receptor Promotes Choroidal Neovascularization by Activating Its Signal Transduction and Tissue Renin-Angiotensin System Am. J. Pathol., December 1, 2008; 173(6): 1911 - 1918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Usui, K. Sugisaki, A. Iriyama, S. Yokoo, S. Yamagami, N. Nagai, S. Ishida, and S. Amano Inhibition of Corneal Neovascularization by Blocking the Angiotensin II Type 1 Receptor Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4370 - 4376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Noda, H. She, T. Nakazawa, T. Hisatomi, S. Nakao, L. Almulki, S. Zandi, S. Miyahara, Y. Ito, K. L. Thomas, et al. Vascular adhesion protein-1 blockade suppresses choroidal neovascularization FASEB J, August 1, 2008; 22(8): 2928 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Izumi-Nagai, N. Nagai, K. Ohgami, S. Satofuka, Y. Ozawa, K. Tsubota, S. Ohno, Y. Oike, and S. Ishida Inhibition of Choroidal Neovascularization with an Anti-Inflammatory Carotenoid Astaxanthin Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1679 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Izumi-Nagai, N. Nagai, K. Ohgami, S. Satofuka, Y. Ozawa, K. Tsubota, K. Umezawa, S. Ohno, Y. Oike, and S. Ishida Macular Pigment Lutein Is Antiinflammatory in Preventing Choroidal Neovascularization Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2555 - 2562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Koto, N. Nagai, H. Mochimaru, T. Kurihara, K. Izumi-Nagai, S. Satofuka, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, et al. Eicosapentaenoic Acid Is Anti-Inflammatory in Preventing Choroidal Neovascularization in Mice Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4328 - 4334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nagai, K. Izumi-Nagai, Y. Oike, T. Koto, S. Satofuka, Y. Ozawa, K. Yamashiro, M. Inoue, K. Tsubota, K. Umezawa, et al. Suppression of Diabetes-Induced Retinal Inflammation by Blocking the Angiotensin II Type 1 Receptor or Its Downstream Nuclear Factor-{kappa}B Pathway Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4342 - 4350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-H. Jung, K. Chu, S.-T. Lee, S.-J. Kim, E.-C. Song, E.-H. Kim, D.-K. Park, D.-I. Sinn, J.-M. Kim, M. Kim, et al. Blockade of AT1 Receptor Reduces Apoptosis, Inflammation, and Oxidative Stress in Normotensive Rats with Intracerebral Hemorrhage J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1051 - 1058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Izumi-Nagai, N. Nagai, Y. Ozawa, M. Mihara, Y. Ohsugi, T. Kurihara, T. Koto, S. Satofuka, M. Inoue, K. Tsubota, et al. Interleukin-6 Receptor-Mediated Activation of Signal Transducer and Activator of Transcription-3 (STAT3) Promotes Choroidal Neovascularization Am. J. Pathol., June 1, 2007; 170(6): 2149 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nagai, Y. Oike, K. Izumi-Nagai, T. Koto, S. Satofuka, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, K. Tsubota, et al. Suppression of Choroidal Neovascularization by Inhibiting Angiotensin-Converting Enzyme: Minimal Role of Bradykinin Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2321 - 2326. [Abstract] [Full Text] [PDF]
|
|